← Browse by Condition
Medical Condition

metastatic renal cancer

Total Trials
1
Recruiting Now
1
Trial Phases
Various
NCT06583070
Recruiting

SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer

Enrollment
300 pts
Location
China
Sponsor
Peking University First Hospit...
View Trial →